NMS 1286937

Drug Profile

NMS 1286937

Alternative Names: NMS-1286937; NMS-P937; PCM-075

Latest Information Update: 17 Mar 2017

Price : $50

At a glance

  • Originator Nerviano Medical Sciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 15 Mar 2017 Trovagene plans a phase I trial for Acute myeloid leukaemia in USA
  • 15 Mar 2017 NMS 1286937 licensed to Trovagene worldwide for the treatment of Acute myeloid leukaemia
  • 15 Mar 2017 Preclinical trials in Acute myeloid leukaemia in USA (PO) before March 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top